News

Eli Lilly and Company has announced an additional $4.5 billion investment in its Lebanon, Indiana manufacturing operations, strengthening the pharmaceutical giant’s long-term commitment…
Read More...

Artera has received U.S. Food and Drug Administration clearance for its ArteraAI Breast test, marking a significant milestone in the use of artificial intelligence for cancer…
Read More...

Halozyme Therapeutics and Oruka Therapeutics have entered into a global exclusive collaboration and licensing agreement focused on advancing innovative drug delivery technology for…
Read More...

Waiv, formerly known as Owkin Dx, has entered into a collaboration with Daiichi Sankyo to support digital pathology biomarker discovery for an antibody-drug conjugate (ADC) development…
Read More...

MSD has announced the successful completion of its acquisition of Terns Pharmaceuticals, Inc., marking a significant move to strengthen its oncology pipeline and expand its portfolio of…
Read More...

Madrigal Pharmaceuticals, Inc. has entered into an exclusive global licensing agreement with Arrowhead Pharmaceuticals to develop and commercialize ARO-PNPLA3, a clinical-stage…
Read More...

Citius Oncology, Inc. has announced a combined financing package of up to $36.5 million aimed at accelerating the commercialization of its cancer therapy LYMPHIR®. The funding includes…
Read More...

Latus Bio, Inc. has secured $97 million in Series A financing to accelerate the development of its gene therapy pipeline, marking a significant milestone for the early-stage biotech…
Read More...

The U.S. Food and Drug Administration has approved LANGLARA™ (insulin glargine-aldy), a biosimilar to Lantus® (insulin glargine), offering a potentially more affordable treatment option…
Read More...

UCB has announced a definitive agreement to acquire Candid Therapeutics in a deal valued at up to $2.2 billion, marking a significant expansion of its immunology pipeline and…
Read More...

The U.S. Food and Drug Administration has approved an expanded indication for Auvelity, allowing its use to treat agitation associated with dementia due to Alzheimer’s disease in…
Read More...

Novo Nordisk has announced the U.S. launch of Ozempic® (semaglutide) tablets, marking a significant expansion of its blockbuster diabetes franchise by introducing an oral version of the…
Read More...

Arrowhead Pharmaceuticals, Inc. has announced that Australia’s Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), marking the first authorized treatment in the…
Read More...

Gilead Sciences has finalized its acquisition of Arcellx, completing a deal valued at approximately $7.8 billion. The transaction marks a strategic expansion of Gilead’s oncology…
Read More...

Novartis has secured approval from the European Commission for its novel therapy Rhapsido, marking a significant advancement in the treatment of chronic spontaneous urticaria (CSU). The…
Read More...

Eli Lilly and Company has announced a definitive agreement to acquire Ajax Therapeutics, a move aimed at strengthening its oncology pipeline with a next-generation treatment for blood…
Read More...

AstraZeneca has received approval from the U.S. Food and Drug Administration for a new self-administered version of its lupus treatment, Saphnelo, marking a significant step forward in…
Read More...

BioMarin Pharmaceutical Inc. has finalized its acquisition of Amicus Therapeutics in an all-cash deal valued at approximately $4.8 billion, marking a significant expansion of its rare…
Read More...

Sun Pharmaceutical Industries Limited has announced a landmark agreement to acquire Organon & Co. in an all-cash transaction valued at approximately $11.75 billion. Under the terms…
Read More...

Leinco Technologies and CellCarta have announced a strategic collaboration to enhance proteomics solutions aimed at supporting immuno-oncology research and the development of targeted…
Read More...